Discovery and Evaluation of TLR-Targeted Immune Agonists
- 5 September 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (18) , 16222-16234
Abstract
Toll-like receptor (TLR) activation converts immunologically inactive tumors into immunologically active tumors by activating tumor residing antigen-presenting cells and recruitment of cytotoxic T lymphocytes. Targeted immune agonists (TIAs) are antibody drug conjugates with small-molecule TLR agonist payloads. The mechanism of action of TIAs involves tumor antigen recognition, Fc gamma-receptor-dependent phagocytosis, and TLR-mediated activation to drive tumor killing by myeloid cells. Several new low DAR anti-HER2 TIAs conjugated with novel TLR7 or dual-TLR7/8 agonists with cleavable and noncleavable linkers were synthesized and profiled. In vitro studies demonstrated that these TIAs activate myeloid cells only in the presence of antigen-expressing cancer cells. Evaluation in ELISpot-based assays confirmed the low immunogenicity of these constructs. Systemic administration of the novel TIAs in tumor-bearing mice resulted in tumor reduction at low doses. These results provide a strong rationale for further development of the TIAs as a novel class of immunotherapeutics.Keywords
This publication has 51 references indexed in Scilit:
- Development and application of an in vitro assay to assess target-independent B-cell activation by targeted TLR7 immune agonistsJournal of Immunological Methods, 2023
- Turning cold tumors hot: from molecular mechanisms to clinical applicationsTrends in Immunology, 2022
- Anti-HER2 therapy in metastatic breast cancer: many choices and future directionsCancer and Metastasis Reviews, 2022
- Antibody–drug conjugates: Recent advances in linker chemistryActa Pharmaceutica Sinica B, 2021
- Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapyBiomaterials, 2018
- Toll-like Receptor Agonist Conjugation: A Chemical PerspectiveBioconjugate Chemistry, 2018
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer Cell, 2015
- Antibody–drug conjugates: current status and future directionsDrug Discovery Today, 2014
- Potent antibody drug conjugates for cancer therapyCurrent Opinion in Chemical Biology, 2009
- Role of Fcγ receptors in cancer and infectious diseaseJournal of Leukocyte Biology, 1994